JP2003503017A5 - - Google Patents

Download PDF

Info

Publication number
JP2003503017A5
JP2003503017A5 JP2001500673A JP2001500673A JP2003503017A5 JP 2003503017 A5 JP2003503017 A5 JP 2003503017A5 JP 2001500673 A JP2001500673 A JP 2001500673A JP 2001500673 A JP2001500673 A JP 2001500673A JP 2003503017 A5 JP2003503017 A5 JP 2003503017A5
Authority
JP
Japan
Prior art keywords
antibody
american type
culture collection
deposited under
type culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001500673A
Other languages
English (en)
Japanese (ja)
Other versions
JP4589586B2 (ja
JP2003503017A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/014599 external-priority patent/WO2000073349A1/en
Publication of JP2003503017A publication Critical patent/JP2003503017A/ja
Publication of JP2003503017A5 publication Critical patent/JP2003503017A5/ja
Application granted granted Critical
Publication of JP4589586B2 publication Critical patent/JP4589586B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2001500673A 1999-05-28 2000-05-25 Ｄｒ４抗体とその利用 Expired - Lifetime JP4589586B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32287599A 1999-05-28 1999-05-28
US09/322,875 1999-05-28
PCT/US2000/014599 WO2000073349A1 (en) 1999-05-28 2000-05-25 Dr4 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2003503017A JP2003503017A (ja) 2003-01-28
JP2003503017A5 true JP2003503017A5 (enExample) 2007-07-19
JP4589586B2 JP4589586B2 (ja) 2010-12-01

Family

ID=23256824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001500673A Expired - Lifetime JP4589586B2 (ja) 1999-05-28 2000-05-25 Ｄｒ４抗体とその利用

Country Status (12)

Country Link
EP (2) EP1181319B1 (enExample)
JP (1) JP4589586B2 (enExample)
AT (1) ATE429450T1 (enExample)
AU (3) AU781952B2 (enExample)
CA (1) CA2374599A1 (enExample)
CY (1) CY1109151T1 (enExample)
DE (1) DE60042066D1 (enExample)
DK (1) DK1181319T3 (enExample)
ES (1) ES2325305T3 (enExample)
IL (1) IL146448A0 (enExample)
PT (1) PT1181319E (enExample)
WO (1) WO2000073349A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281126T3 (es) 1997-03-17 2007-09-16 Human Genome Sciences, Inc. Receptor 5 que contiene un dominio de muerte.
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
JP2002543151A (ja) * 1999-05-04 2002-12-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター５
WO2000073349A1 (en) * 1999-05-28 2000-12-07 Genentech, Inc. Dr4 antibodies and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7115717B2 (en) * 2001-05-18 2006-10-03 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
ES2437992T3 (es) * 2001-05-25 2014-01-15 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a los receptores de TRAIL
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
CA2451680C (en) * 2001-07-03 2011-04-19 Genentech, Inc. Human dr4 antibodies and uses thereof
WO2003013584A1 (en) * 2001-08-09 2003-02-20 Genset S.A. Xafinix agonists and antagonists for use in the treatment of metabolic disorders
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
NZ551428A (en) * 2004-06-18 2010-03-26 Genentech Inc Use of apo2L receptor agonists and NK cells or NK cell activators
MX2007001468A (es) 2004-08-06 2007-03-26 Genentech Inc Ensayos y metodos que utilizan biomarcadores.
AU2005271601A1 (en) 2004-08-06 2006-02-16 Genentech, Inc. Assays and methods using biomarkers
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0606791A2 (pt) 2005-02-02 2010-02-09 Uab Research Foundation métodos de reverter ou prevenir a resistência de uma célula a um agonista do receptor da morte, de triar uma célula quanto a um biomarcador da resistência a um agonista do receptor da morte, de monitorar a resistência a um agonista do receptor da morte em um indivìduo, de induzir seletivamente a apoptose em uma célula alvo expressando um receptor da morte, de tratar de um indivìduo com cáncer, de tratar de um indivìduo com uma doença inflamatória ou autoimune, de bloquear a ligação da proteìna contendo card a um receptor da morte em uma célula, de bloquear a associação de um iap com o receptor da morte e de triar um modulador de uma proteìna contendo card, composição, ácido nucleico isolado, vetor, célula, e, polipeptìdeo isolado
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
PT1915626E (pt) * 2005-08-16 2012-02-03 Genentech Inc Sensibilidade da apoptose a apo2l/trail por ensaio de expressão de galnac-t14 em células/tecidos
WO2008066854A2 (en) * 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
JP5779350B2 (ja) 2007-03-27 2015-09-16 シー レーン バイオテクノロジーズ， エルエルシー 抗体代替軽鎖配列を含む構築物およびライブラリー
US20120128671A1 (en) 2009-05-13 2012-05-24 Lawrence Horowitz Neutralizing molecules to influenza viruses
CA2834776A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
WO2013016714A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
CN110305874A (zh) * 2019-06-19 2019-10-08 浙江省肿瘤医院 长爪沙鼠免疫球蛋白IgG1、IgG2重组蛋白、基因及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP3571337B2 (ja) 1992-02-11 2004-09-29 セル ジェネシス，インコーポレーテッド 遺伝子標的現象による同型遺伝子接合
ES2284199T5 (es) * 1997-01-28 2011-11-14 Human Genome Sciences, Inc. Receptor 4 que contiene dominio de muerte (dr4: receptor 4 de muerte), miembro de la superfamilia de receptores de tnf y unión a trail (apo-2l).
ATE516354T1 (de) * 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
ATE517125T1 (de) * 1998-01-26 2011-08-15 Genentech Inc ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN
IL139419A0 (en) * 1998-06-12 2001-11-25 Genentech Inc Monoclonal antibodies, cross-reactive antibodies and method for producing the same
WO2000073349A1 (en) * 1999-05-28 2000-12-07 Genentech, Inc. Dr4 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2003503017A5 (enExample)
CN106967172B (zh) 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
RU2571515C2 (ru) Гуманизированные антитела к cxcr5, их производные и их применение
RU2486204C2 (ru) Антитела против сd26 и способы их применения
AU2009200269B2 (en) Modulation of NKG2D
JP7262597B2 (ja) 二重特異性抗体及びその作製方法と使用
TWI758558B (zh) Cd96抗體、其抗原結合片段及醫藥用途
US20210155692A1 (en) Anti-ror antibody constructs
CA3099530A1 (en) Anti-interleukin-17a antibody, pharmaceutical composition thereof and use thereof
US9701756B2 (en) Humanized antibody or fragment thereof specific for CD45R0
WO1989009621A3 (en) Compounds for diagnosis and/or therapy of tumours
NZ616992A (en) Anti-ilt7 antibody
NO179615B (no) Monoklonale antistoffer eller fragmenter derav som reagerer med kakektin, cellelinjer som produserer dem, prövesett som omfatter dem, samt anvendelse derav in vitro
CA2185656A1 (en) Protein tyrosine kinase agonist antibodies
CN101778864A (zh) 排斥性引导分子(rgm)蛋白质家族的蛋白的骨形态发生蛋白(bmp)-结合结构域及其功能片段,和它们的用途
KR910009284A (ko) 인체 종양 세포 항원에 특이적인 키메라형 생쥐-인체 a10 항체
WO2018092907A1 (ja) エピトープ均質化抗体パネル、ならびにその作製方法および利用
WO2023109976A2 (zh) Ox40抗体及其医药用途
JP2024510811A (ja) Ｕｐａｒ抗体及びその融合タンパク質
Gattei et al. Characterization of anti‐CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan‐1 in human lymphoma cells
CN113929783B (zh) 抗cd99蛋白单克隆抗体、细胞系及其制备方法和应用
CN118556077A (zh) 一种多特异性抗体及其药物用途
WO2014139425A1 (zh) 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
CN118562015A (zh) 一种针对cd20/cd3的双异性抗体及其制备方法和应用
CN120129701A (zh) 抗ccr8的抗体及其用途